TrialJournal of virology2006

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Mike Westby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.